Literature DB >> 8422292

Rheumatoid arthritis as a risk factor for multiple myeloma: a case-control study.

M Eriksson1.   

Abstract

This population-based case-control investigation was designed to study the importance of rheumatoid arthritis, other diseases and different types of treatment for the risk of developing multiple myeloma. In total, 275 cases with verified myeloma in northern Sweden were matched to as many control subjects. Information about different diseases, drug use, diagnostic X-ray investigations and radiotherapy was obtained through an extensive questionnaire mailed to all living subjects, i.e. cases and controls, and to the next of kin regarding deceased subjects. The study confirmed a suspected association with both rheumatic diseases in general and rheumatoid arthritis specifically. No other disease gave an increased risk for myeloma, but on the contrary, other diseases were in general more common among the controls. In accordance with this finding, use of medications and diagnostic X-ray investigations were also less common in cases than in controls. The study did, however, give some support to a recent finding that the number of X-ray investigations might be a risk factor for myeloma. Earlier radiotherapy on benign indications was more common in cases, whereas radiotherapy for malignant disease was more common among controls in this study.

Entities:  

Mesh:

Year:  1993        PMID: 8422292     DOI: 10.1016/0959-8049(93)90188-l

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Light chain multiple myeloma in a patient with long-standing rheumatoid arthritis.

Authors:  Alexandra Alexopoulou; Spyros P Dourakis; Alexandra Apostolopoulou; Anna Kandyli; Helen Pandelidaki; Athanasios J Archimandritis
Journal:  Clin Rheumatol       Date:  2005-04-23       Impact factor: 2.980

2.  Medication use and multiple myeloma risk in Los Angeles County.

Authors:  Daniel S Nuyujukian; Jenna Voutsinas; Leslie Bernstein; Sophia S Wang
Journal:  Cancer Causes Control       Date:  2014-07-01       Impact factor: 2.506

3.  Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.

Authors:  Normann Steiner; Georg Göbel; Daniela Michaeler; Anna-Luise Platz; Wolfgang Prokop; Anna Maria Wolf; Dominik Wolf; Christina Duftner; Eberhard Gunsilius
Journal:  Blood Adv       Date:  2021-03-23

Review 4.  Epstein-Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis: a case report and review of literature.

Authors:  Yasunobu Sekiguchi; Asami Shimada; Kunimoto Ichikawa; Mutsumi Wakabayashi; Keiji Sugimoto; Keigo Ikeda; Iwao Sekikawa; Shigeki Tomita; Hiroshi Izumi; Noriko Nakamura; Tomohiro Sawada; Yasunori Ohta; Norio Komatsu; Masaaki Noguchi
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.

Authors:  Linda Morris Brown; Gloria Gridley; David Check; Ola Landgren
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113

6.  Multiple myeloma among blacks and whites in the United States: the role of chronic antigenic stimulation.

Authors:  D R Lewis; L M Pottern; L M Brown; D T Silverman; R B Hayes; J B Schoenberg; R S Greenberg; G M Swanson; A G Schwartz; J M Liff
Journal:  Cancer Causes Control       Date:  1994-11       Impact factor: 2.506

7.  Bayesian joint selection of genes and pathways: applications in multiple myeloma genomics.

Authors:  Lin Zhang; Jeffrey S Morris; Jiexin Zhang; Robert Z Orlowski; Veerabhadran Baladandayuthapani
Journal:  Cancer Inform       Date:  2014-12-07

8.  Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies.

Authors:  Kaini Shen; Gufeng Xu; Qing Wu; Daobin Zhou; Jian Li
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

Review 9.  Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Alexei Shimanovsky; Juliana Alvarez Argote; Shruti Murali; Constantin A Dasanu
Journal:  BBA Clin       Date:  2016-05-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.